Life as a consultant cancer pharmacist

steve williamson

Pharmacy has an important role to play regarding new and existing cancer treatments, we chat to Consultant Cancer Pharmacist and Chair of British Oncology Pharmacy Association, Steve Williamson MRPharmS (IPresc), MSc who explains his area of work in more detail.

What was your first contact with pharmacy as a profession?

When I was 16 I visited my local Hospital where my mum worked as an ITU nurse and met the clinical pharmacist who worked on her unit, after talking to him I decided that I wanted to be a hospital pharmacist. Read more Life as a consultant cancer pharmacist

Faculty eight week fast track plan – Week one: Identify peers

faculty-eight-week-blogby Amareen Kamboh MRPharmS PGDipGPP PGCertClinEd FHEA – Senior Teaching Fellow, and programme lead for the JPB postgraduate diploma at the Centre for Inter-Professional Postgraduate Education and Training (CIPPET) at the University of Reading. Education and Training Lead Pharmacist, Educational Programme Director for pre-registration pharmacists at Hampshire Hospitals NHS Foundation Trust.

I began the Faculty Fast Track by familiarising myself with the resources on Royal Pharmaceutical Society (RPS) website that were associated with the peer review, I wrote a down a list of peers that I could contact to assist with the peer review process. Peer review is valuable in supporting the Faculty assessment, and also is a useful validation and quality control to support professional development. The RPS Faculty pages recommend identifying 15 to 20 individuals from a variety of different roles and experience. I chose a range of peers that I have worked with in both academia and secondary care. From this list I identified those who I had mentored and tutored, members of the multidisciplinary team and senior team members and line managers. As well as identifying peers in my current organisation and university role I also contacted team members from the previous trust that I worked for where I first started as an education and training lead. Alongside this, I also felt it was important to obtain feedback from fellow education and training leads from neighbouring trusts, who I work alongside for regional roles in order to capture feedback fully, identify areas for development and evaluate my current working practice. Read more Faculty eight week fast track plan – Week one: Identify peers

Robbery by means of chloroform

By Karen Horn, RPS Librarian and Matthew Johnston, RPS Museum

chloroform-bottleOver 200 people visited the Society over London Open House weekend this year.

They all took a look at the RPS Museum and its varied collection, which includes chloroform bottles from the 1940s.

There are lots of stories about the misuse of chloroform which persist up to the present day, some of which are pretty far-fetched. Read more Robbery by means of chloroform

Faculty eight week fast track plan – my experience

faculty-eight-week-blogAmareen Kamboh MRPharmS PGDipGPP PGCertClinEd FHEA – Senior Teaching Fellow, and programme lead for the JPB postgraduate diploma at the Centre for Inter-Professional Postgraduate Education and Training (CIPPET) at the University of Reading. Education and Training Lead Pharmacist, Educational Programme Director for pre-registration pharmacists at Hampshire Hospitals NHS Foundation Trust.

Contemplation
For a while I have been contemplating starting my Faculty application for professional recognition of advance practice to validate my experience post-registration as an education and training lead pharmacist. Once my development has been recognised post-nominals will be granted that signify my stage in practice. This provides a means of demonstrating to patients, the public and my employer, that I have achieved a designated level, thus providing evidence of capability as a professional.

Read more Faculty eight week fast track plan – my experience

Is ibuprofen bad for your health?

Helen Williams 2by Helen Williams, consultant pharmacist in cardiovascular medicine

A new BMJ study published today examines the effects of nonsteroidal anti-inflammatory drugs (NSAIDS) like ibuprofen on the heart.  The study looked at 10 million people and found taking NSAIDs increased the risk of being taken to hospital with heart failure by 19%.   Sounds frightening doesn’t it?  And it led to some alarming headlines stories in the media. Read more Is ibuprofen bad for your health?

Putting Medicines Safety First in Wales

26.06.14 Royal Pharmaceutical SocietyRob Davies, member of the Royal Pharmaceutical Society’s Welsh Pharmacy Board reflects on the 2015 Medicines Safety Conference and the benefits of attending this year’s forthcoming event.

As a pharmacist and independent prescriber, medicines safety is an issue close to my heart. It is our pre-occupation as a profession, ensuring medicines are appropriate for the patient, are taken safely and as intended. I was excited therefore to attend the RPS Wales annual Medicines Safety Conference last year to hear about strategic plans for Wales and to learn more from practice examples. Read more Putting Medicines Safety First in Wales

Branded, generic and identical medicines – how much should you pay?

jaynelawrenceby Professor Jayne Lawrence, RPS Chief Scientist

Increasingly the public are being encouraged by the Government to take greater responsibility for their own health. In particular, they are being prompted to manage any minor and self-limiting medical condition themselves, which may result in the purchase of an over-the-counter (OTC) medicine.

While it is well recognised that a generic version of a medicine is cheaper than the original branded product, the reasons behind a patient choosing the branded or generic version are complex – in addition to medicine cost, other factors such as advertising, brand loyalty, product packaging or a perception of higher quality can all play a part in the decision a patient makes when purchasing a medicine. Read more Branded, generic and identical medicines – how much should you pay?

Community Innovators – Jay Badenhorst

Jay 150Part of our series on Inspirational Community Innovators

Jay Badenhorst is a community pharmacist that started his career in South Africa. He moved to the UK in 2001 and soon after that decided to stay permanently. He is passionate about pharmacy and the potential that community pharmacy can play in the health and wellbeing of patients.

He once said “In order to be a great leader you don’t need an official title. Whether you’re a pharmacy manager, assistant or technician, you can achieve great things.” He believes that it takes a multifaceted approach to ensuring patients’ best interests are always kept at heart in community pharmacy. Every team members brings a valuable contribution to ensuring every contact counts. He believes it is up to employers to ensure that the professional development of all team members in the pharmacy is ongoing, including investing time into the development of newly qualified pharmacists. Read more Community Innovators – Jay Badenhorst

Identifying Leadership to help build your Faculty portfolio

Susan Ibrahim editedby Susan Youssef MFRPSII MRPharmS

Leadership inspires pharmacists and their teams to achieve high standards of performance and personal development. The Faculty leadership cluster ties into this by allowing you to record the many instances where leadership has been applied successfully as a pharmacist. Initially the way I approached the leadership cluster was by referring to the framework competencies and comparing these to my CPD records and my CV, I then selected suitable examples which I could use for the leadership cluster. Read more Identifying Leadership to help build your Faculty portfolio

Adaptive clinical trials – could patients benefit?

Photo - Liz Allen

by Liz Allen, Visiting Professor, Faculty of Life Sciences and Medicine, King’s College London and Quintiles, Early Clinical Development

What is a clinical trial?
Clinical trials are studies designed to evaluate the effectiveness and safety of potential new medicines. Clinical trials are divided into four phases (Phase I, II, III and real world late phase studies sometime called Phase IV).

Phase 1 requires a small number of subjects, usually healthy volunteers though more recently such studies involve small numbers of patients. As the development moves from phase to phase increasingly large numbers of patients become involved and the cost escalates. It is estimated that about 40% to 50% of drugs that enter phase III studies will fail, by which point a pharmaceutical company will have invested close to one billion pounds. Read more Adaptive clinical trials – could patients benefit?